FAQ

Ophthalmic Solution

Known as: Ophthalmic Solution [Dose Form], Ophthalmic Solutions, Solutions, Ophthalmic 
A sterile solution containing a particular pharmaceutical agent administered to the external eye, usually in the form of droplets. An ophthalmic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1946-2017
020406019462016

Related topics

Related topics

13 relations

Narrower (4)

Carbomer-940Eye Dropslifitegrasttetrahydrozoline

Broader (1)

OPHTHALMIC AGENTS
Ofloxacin Ophthalmic SolutionOphthalmic Solution Dosage Formadministration & dosageaspects of radiation effects
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Ophthalmic Solution
chemical synthesis
Eye Drops
standards characteristics
Carbomer-940
tetrahydrozoline

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients
AIMS To compare the efficacy and safety of 3% diquafosol ophthalmic solution with those of 0.1% sodium hyaluronate ophthalmic… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2012
2012
Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
OBJECTIVE To investigate the dose-dependent efficacy and safety of diquafosol ophthalmic solution for the treatment of dry eye… (More)
Is this relevant?
2010
2010
Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
PURPOSE To determine the aqueous humor concentrations of moxifloxacin and besifloxacin after routine preoperative topical dosing… (More)
Is this relevant?
2008
2008
Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells.
PURPOSE The cytotoxicity of a range of commercial ophthalmic solutions in the presence and absence of preservatives was assessed… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2007
2007
Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
PURPOSE To determine the safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution (Vigamox) in patients having… (More)
  • table 1
  • table 3
  • table 2
  • figure 2
  • figure 1
Is this relevant?
2005
2005
The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
PURPOSE To compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed… (More)
Is this relevant?
2005
2005
Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
PURPOSE To measure the achievable perioperative aqueous concentration of the commercially available topically administered fourth… (More)
Is this relevant?
2005
2005
A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5…
PURPOSE The primary objective of this study was to compare the intraocular pressure (IOP)-lowering efficacy of travoprost 0.004… (More)
Is this relevant?
2005
2005
Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.
OBJECTIVE To investigate the penetration of 0.5% moxifloxacin hydrochloride into the aqueous and vitreous after topical… (More)
Is this relevant?
1976
1976
Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution.
Timolol ophthalmic solutions 0.5 per cent, 1.0 per cent, and 1.5 per cent lowered intraocular pressures significantly in normal… (More)
  • table I
  • table I
  • table II
  • table III
  • table IV
Is this relevant?